Raymond James & Associates Innoviva, Inc. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$14.32 - $19.88 $165,381 - $229,594	-11,549 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$15.39 - $20.25 $30,272 - $39,831	-1,967 Reduced 14.55%	11,549 $223,000
Q4 2021 Feb 08, 2022	BUY	$15.91 - $18.72 $215,039 - $253,019	13,516 New	13,516 $233,000
Q2 2018 Aug 14, 2018	SELL	$13.44 - $17.59 $267,456 - $350,041	-19,900 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$13.8 - $16.99 $274,620 - $338,100	19,900 New	19,900 $332,000

227

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.24B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.